Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype
- 28 March 2003
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 59 (1) , 45-50
- https://doi.org/10.1007/s00228-003-0576-4
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Schizophrenia and tobacco smoking in a Spanish psychiatric hospitalSchizophrenia Research, 2002
- QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patientsJournal of Psychopharmacology, 2002
- Cytochrome P450 Phenotyping/Genotyping in Patients Receiving AntipsychoticsClinical Pharmacokinetics, 2002
- Validation of Methods for CYP2C9 Genotyping: Frequencies of Mutant Alleles in a Swedish PopulationBiochemical and Biophysical Research Communications, 1999
- Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolutionPharmacogenetics, 1997
- What Is the Clinical Importance of Cigarette Smoking in Schizophrenia?The American Journal on Addictions, 1996
- Inhibition of Trazodone Metabolism by Thioridazine in HumansTherapeutic Drug Monitoring, 1995
- Haloperidol Dosing RequirementsJournal of Clinical Psychopharmacology, 1993
- Dextromethorphan and Mephenytoin Phenotyping of Patients Treated with Thioridazine or AmitriptylineTherapeutic Drug Monitoring, 1992
- Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heartToxicology and Applied Pharmacology, 1986